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Background: Few studies have described time-based trends of clinical and demographic characteristics of children
enrolling in HIV and AIDS care and treatment services. We present findings of a study that explored time-based
trends of baseline characteristics among children enrolling into 26 public HIV care facilities in Dar es Salaam,
Tanzania.
Methods: Children enrolled between October 2004 and September 2011 was included in these analyses. The year
of enrollment was used as the primary predictor of interest, and log linear and linear regressions model were used
to analyze dichotomous and continuous variables respectively. P-values under 0.05 were considered significant.
Results: Among the 6,579 children enrolled, the proportion with advanced disease at enrollment increased from 35%
to 58%, mean age increasing from 5.0 to 6.2 years (p < 0.0001), proportion of children less than 2 years decreased
from 35% to 29%. While the median hemoglobin concentration rose from 9.1 g/dl to 10.3 g/dl (P <0.0001), proportion
with a history of past TB dropped from 25% to 12.8% (P < 0.0001). Over time, health centers and dispensaries enrolled
more children as compared to hospitals (P < 0.0001). Temeke district, which has the lowest socioeconomic status
among the three districts in Dar es Salaam, had a significant increase in enrollment from 22% to 25% (P = 0.02).
Conclusion: We found that as time progressed, children were enrolled in care and treatment services at an older age
sicker status as evidenced by increase in mean age and more advanced disease stage at first contact with providers.
We recommend more efforts be focused on scaling up early HIV infant diagnosis and enrollment to HIV care and
treatment.
Keywords: HIV, AIDS, PediatricBackground
The public provision of free pediatric antiretroviral
treatment (ART) services in Tanzania started in 2004.
Country-wide HIV and AIDS data show that the pro-
portion of eligible children receiving highly active anti-
retroviral therapy (HAART) has remained relatively
constant over the past 5 years at about 25% [1]. Des-
pite revisions of national pediatric ART guidelines to* Correspondence: dsando.tz@gmail.com
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approximately 76% of ART eligible children have yet
to access HAART services [2,3].
Poor coverage and utilization of ART services has ser-
ious repercussions, especially for children living with
HIV. Approximately 50% of HIV infected children not
initiated on ART die before the age of 2 years, and of
the surviving, about one third die before 5 years of age
[4,5]. Early initiation of HAART leads to a significant
decline of early mortality [5-7], with up to 90% survivalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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fected children were found to have high two year mortality
of 547 per 1000 as compared to 166 per 1000 of HIV
negative children of HIV positive mothers, and 128 per
1000 of HIV negative mothers [6]. The 2012 Tanzania
Ministry of Health and Social Welfare (MOHSW) report
shows that only 56% of children living with HIV are
enrolled in pediatric HIV care and monitoring services [9].
The observed low enrollment may be attributed to several
factors including poor access to early infant diagnosis of
HIV (EID); insufficient number of trained clinicians in the
management of pediatric HIV/AIDS; limited health care
infrastructure; socio-cultural factors; lack of affordable
simple diagnostic HIV testing technologies for children
less than 18 months; limited experience with simplified
standardized treatment guidelines; and lack of affordable
practicable pediatric antiretroviral (ARV) formulations,
which further complicates the scaling up of the national
pediatric ART program [4,10,11].
The rapid disease progression and high mortality,
which may occur in untreated children, raises the need
for urgent scaling up of the ART program to bolster
access and coverage [11-13]. Sub-optimal coverage and
poor retention for patients who are on HAART exposes
the need for robust evaluations of pediatric ART ser-
vices. Very few analyses have described trends in charac-
teristics of children at enrollment of HIV care and
treatment programs [14-16]. This information is essen-
tial to understanding the progress achieved thus far in
increasing enrollment, as well as in designing strategies
aiming to improve access to HAART for the large num-
ber of HIV infected and untreated children.
Since 2004, Management and Development for Health
(MDH) (and its predecessor) has provided technical sup-
port to the implementation of pediatric HIV care and
treatment services through the President’s Emergency
Plan for AIDS Relief (PEPFAR). This program was rolled
out in a wide range of public and private health care
facilities in Dar es Salaam, Tanzania. Despite a rapid
increase in the number of HIV-positive patients enrolled
in care and treatment since the inception of the pro-
gram, children continue to be under-represented. This
study describes temporal trends in baseline demographic
and clinical characteristics amongst children enrolled in
the ART program in 26 care and treatment clinics
(CTCs) in Dar es Salaam.
Methods
Study population
Between October 2004 and September 2011, 6579 chil-
dren under 15 years of age were enrolled in the national
ART program in 26 CTCs located in the Dar es Salaam
region. The facilities include five secondary level hospi-
tals and 21 primary health care (PHC) clinics that aredispersed within the 3 districts of Dar es Salaam. All
facilities offered free health care for HIV infected adults
and children. Children who were enrolled in HIV Care
and Treatment, both those started on ART and in care
for monitoring were included in this analysis. Since
the start of the ART program in September 2004 to
September 2011, there has been no change in pediatric
ART regimens. All enrolled children below 3 years were
receiving Zidovudine (AZT) + Lamivudine (3TC) + Nevi-
rapine (NVP) while those eligible and 3 years or above
were receiving Zidovudine (AZT) + Lamivudine (3TC) +
Nevirapine (NVP)/EFAVIRENZ (EFV) regimen.
Data collection
The design of the study is a retrospective analysis using
routine collected data. At the enrollment visit demo-
graphic characteristics were recorded including age, sex,
marital status of caretakers and past therapeutic and
clinical history. Children were also screened for tubercu-
losis (TB) symptoms using standardized questionnaire to
identify TB suspect, who then took a Acid Fast Bacilli
(AFB) test for their sputum, or chest x-ray. History of
diarrheal disease for both acute and chronic episodes
was documented. Investigation for anemia, assessment
of functional status, nutritional status and WHO clinical
stage of the disease were also done. However wasting
syndrome was not collected for year 2011 due to change
of the tools. Immunological and biochemical tests were
performed to evaluate CD4, alanine aminotransferase
(ALT), and hemoglobin (HB) levels.
Study variables
Time trends of clinical and demographic variables with
programmatic implications were examined. The vari-
ables were: sex, age at enrollment (<2, 2–10, >10 years),
WHO clinical stage at enrollment (categorized as ad-
vanced disease (stages III and IV) or moderate disease
(stages I and II)), CD4 cell count for those ≥ 5 years,
CD4 cell percentage for those <5 years, past history and
current status of TB disease, HB level and presence of
OIs. Diarrhea, wasting syndrome, season of the year,
facility level, and district were also included. Due to
fewer children’s enrolled during the end of 2004 at the
start of the program, 2004 enrollment is combined with
2005 in the analysis.
Statistical methods
Categorical variables are presented in the tables as num-
ber (percent), and continuous variables are presented as
median (interquartile range) or mean (standard devi-
ation). In all analyses, year of enrollment was used as the
predictor. All dichotomous variables were analyzed using
log-binomial regression. These included WHO clinical
stage, past history of TB, current TB symptoms, presence
Table 1 Baseline characteristics of the pediatric patients
enrolled in care and treatment clinics
N (%) or
median (IQR)
Number of Children 6579
Proportion children among enrollee 14
Male, n (%) 3209 (48.78)
Age, Mean (sd) 5.2 (4.2)
Age ≥10 years, n (%) 1284 (19.52)
Age < 2 years, n (%) 2416 (37.23)
WHO clinical stages III & IV, n (%) 2937 (50.61)
Proportion with wasting at enrollment (n = 6806) 1109 (29.93)
CD4 cell %, median (IQR) (<5 yrs) n = 3219 18 (12–26)
CD4 cell count (≥5 yrs) n = 3271 330 (125–586)
Proportion with TB history, n (%) 730 (14.54)
Proportion with TB current, n (%) 333 (6.38)
Hemoglobin, median (IQR) 9.8 (8.6-11)
Proportion with diarrhea, n (%) 542 (10.21)
Proportion with OI 894(13.59)




Season of the year
December - March 1070 (16.26)
April - May 1091 (16.58)
June - September 2070 (31.46)
October - November 2348 (35.69)
Level of health facility, n (%)
Hospital 3600 (55.23)
Health Center 2549 (39.11)
Dispensary 369 (5.66)
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modeled using linear regression including age, body mass
index (BMI) z-score, weight-for-length (WFL) z-score and
HB level. To assess the statistical significance of time
trends with nominal categorical variables with more than
two levels, such as district, season of enrollment and level
of the health facility, we used nominal polytomous logistic
regression. Stepwise restricted cubic splines [17] were
used to assess non-linearity of time trends in relation to
dichotomous and continuous outcome of interest. P-
values under 0.05 were considered significant.
This study project received IRB approval from the Na-
tional Institute of Medical Research (NIMR) in Tanzania.
A written consent was obtained from parents or guard-
ians of the children involved in this study.
Results
Table 1 presents the characteristics of 6579 children
enrolled in 26 public CTCs in Dar es Salaam. Forty-
nine percent were male. The mean age was 5.2 years (sd:
4.2). Thirty-seven percent were less than 2 years old and
20% were 10 or more years old at enrollment. Fifty-one
percent presented with advanced WHO pediatric stage
(III & IV), and 30% were wasted. For the 49% of the
children enrolled at age less than 5 years, their median
CD4 percentage was 18 (IQR: 12–26); for those enrolled
at age 5 or above, their median CD4 count was 330 cells/
mm3 (IQR: 125–586). Fourteen percent had past medical
history of pulmonary TB, and 6.4% presented with TB at
their first visit to the clinic. The median HB concentra-
tion was 9.8 g/dl (IQR: 8.6-11.0), and 14% of the children
had at least one type of OI at enrollment. Approximately
4% presented with signs of wasting syndrome and 10%
had diarrheal disease. Fifty-five percent of the children
were enrolled in secondary health care facilities and 45%
of total enrollment occurred in Ilala district.
Table 2 presents demographic and clinical character-
istics by year of children enrolled between October
2004 and September 2011. The number of new chil-
dren enrolled increased from 2004/05 to 2008 then
started to decrease in 2009. The mean age at enroll-
ment increased from 5.0 (3.9) in 2004/05 to 6.2 years
(std: 4.2: P = <0.0001) in 2011. The proportion of chil-
dren enrolled at the age of 10 years or above increased
from 16% in 2004/5 to 27% in 2011 (P <0.0001), and
the fraction of children enrolled at the age of 2 years
or less decreased from 35% in 2005 to 29% in 2011
(P = <0.0001). The proportion of children enrolled in
Temeke district, which has the lowest socioeconomic
status of the three districts, rose from 22% in 2004/5
to 25% in 2011 (P = 0.02). The proportion of children
seen in health centers and dispensaries, as compared
to the hospitals, increased over the 7 years during the
follow up period and was significant (p <0.0001).We also observed an increase in children presenting
with advanced clinical stage (WHO pediatric stage III
and IV) from 35% in 2004/5 to 58% in 2011 (p = 0.03).
There was a decrease in the percent of children present-
ing with a history of TB disease from 25% in 2004/5 to
13% in 2011 (p <0.0001). The median HB level increased
from 9.1 mg/dl (IQR: 8.1-10.4) in 2004/5 to 10.3 mg/dl
Table 2 Characteristics of children enrolled in care and treatment services by Calendar year
Year of enrollment to Care and treatment
2004/05 2006 2007 2008 2009 2010 2011 P-value
Average number of children enrolled
monthly
43.6(7.8) 88.1 (15.8) 91.2 (16.4) 106.5 (19.1) 90.9 (16.3) 74.0 (13.3) 62.2 (11.2) 0.01
Percent of children among total enrollees
(total/% children)
(3394) 0.18 (5872) 0.18 (9116) 0.12 (18257) 0.07 (18183) 0.06 (17760) 0.05 (14000) 0.04 <0.01
Male, n (%) 286 (46.8) 501 (47.4) 541 (49.5) 643 (50.3) 532 (48.8) 427 (48.09) 279 (49.8) 0.38
Age, Mean (std) 5.0 (3.9) 3.7 (4.1) 5.5 (4.0) 5.2 (4.2) 5.5 (4.3) 5.7 (4.2) 6.2 (4.3) <0.01
Age ≥10 years, n (%) 99 (16.3) 133 (12.8) 209 (19.7) 242 (19.1) 240 (22) 216 (24.60) 145 (26.8) <0.01
Age < 2 years, n (%) 212 (34.9) 574 (55.1) 357 (33.6) 457 (35.9) 380 (34.9) 279 (31.78) 157 (29.) <0.01
WHO clinical stages III & IV, n (%) 122 (34.9) 306 (45.3) 538 (53.4) 649 (51.5) 556 (51) 446 (50.86) 320 (57.87) 0.03
Proportion with wasting 8 (33.3) 22 (39.3) 235 (34.4) 327 (29.3) 284 (27.6) 233 (29.4) – 0.01
CD4 cell % (<5 yrs), median (IQR) 16 (9-2) 21 (12-31) 16 (11-21) 17 (12-3) 18 (13-3) 19 (12-26) 18 (14-25) 0.89















Proportion with TB history, n (%) 98 (25.32) 38 (14.2) 148 (19.2) 157 (13.4) 131 (12.4) 92 (10.9) 66 (11.8) <0.01
Percent with TB symptoms, n (%) 57 (13.8) 13 (3.9) 36 (4.2) 75 (6.3) 62 (5.8) 52 (6.1) 38 (6.8) 0.07
Hemoglobin, median (IQR) 9.1 (8.1-10.4) 9.4 (8.4-10.7) 9.5 (8.3-10.6) 9.8 (8.6-11) 9.8 (8.7-11) 10.2 (9-11) 10.3 (9-11) <0.01
Proportion with OI, n (%) 48 (7.9) 28 (2.7) 163 (14.9) 247 (19.3) 185 (16.9) 122 (13.7) 101 (18.) <0.01
Proportion with diarrhea, n (%) 67 (15.5) 38 (11.4) 91 (10.5) 142 (11.8) 107 (9.9) 48 (5.6) 49 (9.2) <0.01
District of enrollment, n (%)
Ilala 252 (42.5) 489 (47.6) 528 (48.8) 580 (45.4) 493 (45.2) 363 (40.9) 237 (42.3) 0.02
Kinondoni 210 (35.4) 298 (29) 301 (27.8) 321 (25.1) 307 (28.1) 289 (32.6) 183 (32.7)
Temeke 131 (22.1) 240 (23.4) 252 (23.3) 377(29.5) 291 (26.7) 236 (26.6) 140 (3)
Season of enrollment
December - March 181 (29.6) 269 (25.5) 333 (30.4) 362 (28.3) 404 (37) 297 (33.5) 224 (4?) <0.01
April - May 62 (10.2) 191 (18.1) 157 (14.4) 240 (18.8) 177 (16.2) 163 (18.4) 80 (14.3)
June - September 254 (41.6) 366 (34.6) 402 (36.8) 450 (35.2) 349 (31.9) 272 (30.6) 256 (10.9?)
October - November 114 (18.7) 231 (21.9) 202 (18.5) 226 (17.7) 162 (12.7) 156 (17.6)
Level of health facility, n (%)
Hospital 486 (81.9) 706 (68.7) 611 (56.5) 674 (52.7) 526 (48.2) 391 (44.) 206 (36.8) <0.01
Health Center 95 (16.) 317 (30.9) 470 (43.5) 585 (45.8) 455 (41.7) 371 (41.8) 256 (45.7)
Dispensary 12 (2) 4 (0.4) 0 (0) 19 (1.5) 110 (10.) 126 (14.19) 98 (17.50)
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crease in the proportion of children with diarrhea
from16% in 2004/5 to 9% in 2011 (p < 0.0001). However,
consonant with the increase in advanced disease, there
was an increase in the proportion of children with OI’s
from 8% in 2004/5 to 18% in 2011 (p < 0.0001). There
was no significant non-linearity evident in any of the
time trends studied.
Discussion
This study is among the few studies that have described
characteristics of children enrolling in HIV care and
treatment programs in sub-Saharan Africa. Even with
the remarkable achievement in scaling up of pediatricART services, still children are enrolled into the program
at an older age. The increasing number of pregnant
women who are living with HIV receiving ARV prophy-
laxis, and large number of ART adults patients in our
HIV Care and Treatment program could lead to reduced
HIV transmission to children and thus affecting the
enrollment numbers. However, this is contrary to the
expectation that an increase in coverage would result in
enrollment of children at younger ages due to observed
low access to HIED services, which jeopardize the effect-
iveness of PMTCT program. A pediatric program in
Thailand also reported a high median age at HAART
initiation of 7.3 years (IQR: 5.0-9.4) for children [18].
Late enrollment of children may be attributed to weak
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natal care and postnatal care clinics, and lack of skilled
human resource in management of pediatric AIDS. Des-
pite WHO recommendations of ART initiation of HIV
infected children younger than 12 months, irrespective
of the clinical and immunological stage since April 2008,
efforts to increase enrollment are yet to yield any
remarkable results [19-21]. Several of the facilities pro-
viding pediatric ART services in South Africa, however,
have reported success in enrolling 53% of eligible chil-
dren under 2 years old [19]. This indicates that with
appropriate strategies, pediatric ART programs in sub-
Saharan Africa are capable of enrolling children at much
younger ages. Alternatively, with expanding access to
ART, our program may be including older children who
have previously been not reached, and the efforts to
enroll young children will be noted in the years.
Findings show that children enrolled in recent years
are more likely to present with late WHO clinical stages
of HIV. This indicates that children are more likely to be
identified and enrolled into care after they have devel-
oped AIDS, which in most cases is later in life. In our
setting, several factors are likely associated with late
enrollment including poorly accessible diagnostics prob-
lems, low health seeking behavior, poor attendance at
postnatal clinics, lack of effective community health
services and poorly implemented counseling and testing
services for HIV, including provider initiated counseling
and home-based care testing.
We also found a decrease in the proportion of enrolled
children with a history of TB, and a decrease in the
percent of those that screened TB positive. This overall
decrease in TB burden is similar to trends shown in a
cohort of HIV infected children in Uganda, where they
observed a reduction of up to 70% of TB cases [22].
However, TB is still a threatening OI among HIV
infected patients. Data from Indonesia suggests that up
to 27% of all TB cases are seen in children. In this study
we found that only 6% of enrolled children had TB,
while a cohort of children in Uganda had a TB preva-
lence of 9.5% [22,23]. Intensive TB screening programs
at all CTCs, and ongoing capacity building strategies to
support service providers in identification and prompt
management of TB cases, are possible factors for the
achievements in a reduction of TB cases.
The median HB level increased annually since the start
of study. This is contrary to the expectation that chil-
dren who were enrolled at a late stage of disease and at
an older age, were more likely to present with a decline
in their clinical status, which could be explained by the
effects of age on HB concentration. However, the finding
may indicate a ‘survivor bias’ in our dataset, in that those
whose who were sicker had died. Anemia has been re-
ported as a prevalent condition in HIV infected children,and it has also been associated with age, CD4 count and
clinical or immunological status [22,24,25].
Our study has several strengths and limitations
This analysis included data collected from a large num-
ber of children enrolled in health facilities at different
levels of the health care delivery system. Limitations
include that only public facilities were included, which
may limit generalizability. According to the MDH pro-
gram progress report, by the end of September 2012,
25% of the HIV patients in DSM were receiving HIV
treatment services in private facilities. Given that the
provision of ART services is provided free of charge and
supported equally in both public and private sectors,
and that both sectors use the same national standards,
these trends can be inferred to private facilities in Dar es
Salaam.
Conclusions
In conclusion, despite efforts to scale up HIV screening
and care and treatment services, children are generally
being enrolled at a late stage of HIV disease in the Dar
es Salaam region. There is a need to increase the access
to HIV Exposed Infant Diagnosis services with corre-
sponding efforts to improve retention and provide timely
DBS results to speed up early initiation on ART.
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